Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn’s disease

Monia Marchetti, Nicola Liberato (), Antonio Sabatino and Gino Corazza

The European Journal of Health Economics, 2013, vol. 14, issue 6, 853-861

Abstract: TD is a cost-effective treatment in newly diagnosed CD patients with luminal moderate-to-severe disease, and sensitivity analysis showed the result to be robust. Copyright Springer-Verlag 2013

Keywords: Cost-effectiveness; Crohn’s disease; Infliximab; Step-up; Top-down; I00; I19 (search for similar items in EconPapers)
Date: 2013
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://hdl.handle.net/10.1007/s10198-012-0430-7 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:14:y:2013:i:6:p:853-861

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-012-0430-7

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().